Behling H, Krafft W, Wagner F
Zentralbl Gynakol. 1986;108(11):684-90.
According to our experiences the incorporation of 3H-thymidine in ovarian cancer cells determined by autoradiography represents a method of additional tumour characterization. The in-vitro-tests allow roughly hints about the efficiency of an intended therapy in 49 patients suffering from ovarian cancer. High risk patients may be excluded from a chemotherapy, if the incorporation of thymidine is low. For this decision we also evaluate the results of oncobiogram and clinical parameters. The 3H-thymidine incorporation enables to elect an individual kind of therapy for any patient with regard to success and duration of treatment.
根据我们的经验，通过放射自显影法测定卵巢癌细胞中3H-胸腺嘧啶核苷的掺入情况，是一种辅助肿瘤特征化的方法。体外试验能大致提示针对49例卵巢癌患者的预期治疗效果。如果胸腺嘧啶核苷掺入率低，高风险患者可排除在化疗之外。对于这一决策，我们还会评估肿瘤生物图谱和临床参数的结果。3H-胸腺嘧啶核苷掺入情况有助于根据治疗的成功率和持续时间为每个患者选择个体化的治疗方案。
